Manhattan Labs to Offer CombiMatrix Miscarriage Array Tests to New York Clients | GenomeWeb

NEW YORK (GenomeWeb News) – Manhattan Labs will market CombiMatrix's chromosomal microarray testing services to customers in the New York City metropolitan area, the firms said today.

Manhattan Labs CEO Ken Cerney said in a statement that the independent clinical laboratory opted to offer the test as part of a new focus on miscarriage management, and added that his firm "believes in the growing importance and clinical advantages microarray testing provides for appropriate patients."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.